Back
Speaker illustration

undefined undefined undefined

Presentations

Misdiagnosis rates in ATTR-CM patients and associated symptoms

Event: ESC Congress 2025

Topic: Infiltrative Myocardial Disease

Session: Improving diagnosis of cardiac amyloidosis

Access
Like
Thumbnail

Addressing unmet needs in ATTR-CM management: insights from EU4 cardiologists

Event: ESC Congress 2025

Topic: Infiltrative Myocardial Disease

Session: Improving treatment of transthyretin cardiac amyloidosis

Access
Like
Thumbnail

Changes in the diagnostic landscape of transthyretin amyloid cardiomyopathy (ATTR-CM): a comparison of tests ordered and test Intervals in 2020 Q4 and 2023 Q4

Event: ESC Congress 2024

Topic: Infiltrative Myocardial Disease

Session: The different faces of cardiac amyloidosis

Access
Like
Thumbnail

ESC 365 is supported by

novartis Explore sponsored resources